Verastem, Inc.
NASDAQ:VSTMBiotechnology
-$0.00 today
- Market cap
- $865.72M
- Beta
- 0.27
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$1.97
Volume 3.97M
Average 2.58M
VSTM EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Verastem, Inc.NASDAQ: VSTM
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$35.93M, compared with -$51.9M a year earlier. Trailing-twelve-month EBITDA was -$191.95M.
Context
- EBITDA amounted to 671.6% of revenue in FY2025, down 587.1 pp from a year earlier.
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of -$137.53M (+33.8%) for the fiscal year ending Dec 2026, a step up from the -64.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$35.93M-11.6% QoQ
- Last fiscal yearDec 2025
- -$207.61M-64.9% YoY
- LTMMar 2026
- -$191.95M-32.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +30.8% | -67.8% | -98.5 pp |
| 1 year | -64.9% | +33.8% | +98.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (207.61M) USD
- Year-over-year change
- -64.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (207.61M) | -64.9% |
| FY2024 | 2024-12-31 | (125.86M) | -51.3% |
| FY2023 | 2023-12-31 | (83.17M) | -16.2% |
| FY2022 | 2022-12-31 | (71.56M) | -17.0% |
| FY2021 | 2021-12-31 | (61.16M) | — |
EBITDA vs competitors
How VSTM compares with its peers on the latest reported figures
- VSTM's LTM Mar 2026 EBITDA of -$191.95M is the lowest of the 11 companies compared; the peer median is -$79.11M.
- Its year-over-year change of -32.3% is the 9th highest of 10, against a peer median of +7.0%.
- EBITDA amounts to 387.1% of revenue for VSTM, versus a peer median of 371.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$43.73M | +9.5% | — | 8329.5% | |
| LTM Mar 2026 | -$58.85M | +7.0% | — | — | |
| LTM Jun 2024 | -$63.57M | — | — | 979.5% | |
| LTM Mar 2026 | -$72.53M | +7.7% | — | 257.0% | |
| LTM Mar 2026 | -$76.13M | +39.6% | — | 455.3% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$82.08M | +0.7% | — | — |
| LTM Mar 2026 | -$100.38M | -3.7% | — | 287.9% | |
| LTM Jun 2026 | -$127.04M | +36.8% | — | 74.8% | |
| LTM Mar 2026 | -$134.03M | -1.8% | — | — | |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | -$168.12M | -90.3% | — | — |
| LTM Mar 2026 | -$191.95M | -32.3% | — | 387.1% | |
| Peer median (excluding VSTM) | -$79.11M | +7.0% | — | 371.6% | |
Competitors are the stored peer set for VSTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.05M | 2.6M | 0 | 10M | 30.91M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 5.3M |
| Gross Profit | 2.05M | 2.6M | 0 | 10M | 25.62M |
| Gross Margin | 100.0% | 100.0% | — | 100.0% | 82.9% |
| Research & Development | 39.35M | 50.56M | 61.36M | 81.33M | 114.6M |
| Selling, General & Admin | 24.12M | 24.98M | 30.73M | 43.62M | 81.15M |
| Operating Expenses | 63.46M | 75.53M | 92.08M | 124.96M | 195.75M |
| Depreciation & Amortization | 72K | 118K | 62K | 26K | 728K |
| EBITDA | (61.16M) | (71.56M) | (83.17M) | (125.86M) | (207.61M) |
| EBITDA Margin | -2978.9% | -2756.4% | — | -1258.6% | -671.6% |
| Operating Income | (61.41M) | (72.94M) | (92.08M) | (114.96M) | (170.13M) |
| Operating Margin | -2991.2% | -2809.6% | — | -1149.6% | -550.3% |
| Interest Income | 181K | 1.22M | 6.21M | 4.15M | 4.07M |
| Interest Expense | 9.97M | 2.14M | 4.14M | 4.56M | 1.14M |
| Other Income / Expenses | (9.79M) | (875K) | 4.72M | (15.5M) | (39.34M) |
| Income Before Tax | (71.2M) | (73.81M) | (87.37M) | (130.45M) | (209.47M) |
| Pre-Tax Margin | -3468.1% | -2843.3% | — | -1304.5% | -677.6% |
| Income Tax Expense | 0 | 0 | 0 | 185K | 0 |
| Net Income | (71.2M) | (73.81M) | (87.37M) | (130.64M) | (209.47M) |
| Net Margin | -3468.1% | -2843.3% | — | -1306.4% | -677.6% |
| EPS (Basic) | (4.92) | (4.57) | (3.96) | (3.66) | (3.02) |
| EPS (Diluted) | (4.92) | (4.57) | (3.96) | (3.66) | (3.02) |
| Weighted Avg Shares | 14.53M | 16.14M | 22.05M | 35.71M | 69.31M |
| Weighted Avg Shares (Diluted) | 14.53M | 16.14M | 22.05M | 35.71M | 69.31M |
Verastem, Inc.
NASDAQ:VSTM
Intrinsic Alpha fair value
Locked
Current Price
$6.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.